Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kymera Therapeutics, Inc.

46.18
-0.1700-0.37%
Post-market: 46.180.00000.00%17:31 EDT
Volume:501.45K
Turnover:23.29M
Market Cap:3.24B
PE:-14.84
High:47.30
Open:46.74
Low:46.00
Close:46.35
Loading ...

Kymera Therapeutics initialed with Early-Stage Biotech at Goldman Sachs

TIPRANKS
·
15 Jul

When the market’s hot, go where it’s not: Biotech’s position of opportunity for FY26

LiveWire
·
15 Jul

Morgan Stanley Assumes Coverage of Kymera Therapeutics (KYMR) Stock with Overweight Rating

Insider Monkey
·
10 Jul

Brookline Capital Markets Sticks to Their Buy Rating for Kymera Therapeutics (KYMR)

TIPRANKS
·
07 Jul

Kymera Therapeutics: Buy Rating Backed by Innovative Drug Discovery and Strategic Partnerships

TIPRANKS
·
03 Jul

Kymera Therapeutics assumed with an Overweight at Morgan Stanley

TIPRANKS
·
03 Jul

BVF Partners Reports Acquisition of Kymera Therapeutics Common Shares

Reuters
·
02 Jul

Kymera Therapeutics management to meet with B. Riley

TIPRANKS
·
01 Jul

Baker Bros. Advisors LP Reports Acquisition of Common Shares in Kymera Therapeutics Inc

Reuters
·
01 Jul

Kymera Therapeutics price target raised to $54 from $51 at BofA

TIPRANKS
·
30 Jun

Kymera Therapeutics Held Annual Shareholders Meeting

Reuters
·
28 Jun

Kymera Therapeutics Is Maintained at Outperform by Oppenheimer

Dow Jones
·
28 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Estee Lauder, TC Energy, Cancer test makers

Reuters
·
28 Jun

Kymera Therapeutics : Oppenheimer Cuts Target Price to $53 From $56

THOMSON REUTERS
·
27 Jun

Kymera Therapeutics 5.043M share Spot Secondary priced at $44.00

TIPRANKS
·
27 Jun

BRIEF-Kymera Therapeutics Announces Pricing Of $250 Million Public Offering

Reuters
·
27 Jun

Kymera Therapeutics Inc - Common Stock Priced at $44.00 per Share, Pre-Funded Warrants at $43.9999

THOMSON REUTERS
·
27 Jun

Kymera Therapeutics Inc - Kymeria Therapeutics Prices $250.8 Mln Public Offering

THOMSON REUTERS
·
27 Jun

Kymera Therapeutics Is Maintained at Overweight by Wells Fargo

Dow Jones
·
26 Jun

TD Cowen Keeps Their Buy Rating on Kymera Therapeutics (KYMR)

TIPRANKS
·
26 Jun